90
Growth Score
pts
Heat Score
31 pts
Company Performance Metrics
Score
Trend
AI Content may contain mistakes and is not legal, financial or investment advice.Learn more.
Growth Score - The measure of growth based on company activity, operational metrics, and investments
Growth Trend - The change in the growth score over the given time period
Heat Score - The measure of the market interest, media activity, and Crunchbase profile activity
Heat Trend - The change in the heat score over the given time period
Recent Milestones
Raised Funding Round
Jan 1, 1970
Lorem ipsum dolor sit amet, consectetur
Raised Funding Round
Jan 1, 1970
Lorem ipsum dolor sit amet, consectetur
See more interactive data and historical milestones on desktop for the best experience
149905
ConSynance Therapeutics is a clinical-stage drug development company based in Rensselaer, New York.
John Maki: PresidentPast Role: Vicus Therapeutics, President and CEO- Shuang Liu: CEOPast Role: ConSynance Therapeutics, Founder and President
About the Company
ConSynance Therapeutics is a clinical-stage drug development company based in Rensselaer, New York. ConSynance’s pipeline includes innovative treatments for non-alcoholic steatohepatitis (NASH), the orphan disease Prader-Willi Syndrome (PWS), and irritable bowel syndrome (IBS). They believe that these assets have major competitive advantage over
existing or in-development agents. These investigational therapeutics are the output of several years of previous drug discovery efforts at Albany Molecular Research, Inc (AMRI). The founders of ConSynance Therapeutics, Inc. were on the leadership team at AMRI during this effort and have licensed these assets into ConSynance as a vehicle for accelerating their development.
Women Founded
Women Led
